Show simple item record

dc.contributor.authorSpencer, K.en
dc.contributor.authorButenschoen, H.en
dc.contributor.authorAlger, E.en
dc.contributor.authorBachini, M.en
dc.contributor.authorCook, Natalieen
dc.date.accessioned2024-07-31T09:57:18Z
dc.date.available2024-07-31T09:57:18Z
dc.date.issued2024en
dc.identifier.citationSpencer K, Butenschoen H, Alger E, Bachini M, Cook N. Amplifying the Patient's Voice in Oncology Early-Phase Clinical Trials: Solutions to Burdens and Barriers. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2024 Jun;44(3):e433648.en
dc.identifier.pmid38857456en
dc.identifier.doi10.1200/edbk_433648en
dc.identifier.urihttp://hdl.handle.net/10541/627118
dc.description.abstractDose-finding oncology trials (DFOTs) provide early access to novel compounds of potential therapeutic benefit in addition to providing critical safety and dosing information. While access to trials for which a patient is eligible remains the largest barrier to enrollment on clinical trials, additional direct and indirect barriers unique to enrollment on DFOTs are often overlooked but worthy of consideration. Direct barriers including financial costs of care, travel and time investments, and logical challenges including correlative study designs are important to bear in mind when developing strategies to facilitate the patient experience on DFOTs. Indirect barriers such as strict eligibility criteria, washout periods, and concomitant medication restrictions should be accounted for during DFOT design to maintain the fidelity of the trial without being overly exclusionary. Involving patients and advocates and incorporating patient-reported outcomes (PROs) throughout the process, from initial DFOT design, through patient recruitment and participation, is critical to informing strategies to minimize identified barriers to offer the benefit of DFOTs to all patients.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/edbk_433648en
dc.titleAmplifying the patient's voice in oncology early-phase clinical trials: solutions to burdens and barriersen
dc.typeArticleen
dc.contributor.departmentUniversity of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom.en
dc.identifier.journalAmerican Society of Clinical Oncology Educational Booken
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record